Apr. 25, 2013News & Opinions
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced today that their new cGMP custom biopharmaceutical manufacturing 'biologics plant of the future' will open in June 2013.
Feb. 05, 2013News & Opinions
Aesica, an international contract manufacturing organization (CMO), has appointed Jarrett Palmer as Operations Director of its formulated products business unit.
Dec. 18, 2012News & Opinions
Aesica, the global contract manufacturing organisation (CMO), announces its second major innovation board partnership following the recent annual Genesis conference, a famed hotbed of future innovation.
Sep. 27, 2012News & Opinions
Hovione today announced the expansion of its solutions to solve issues of poor bioavailability, patient acceptability and the enabling of optimal delivery for non-oral routes of administration.
Sep. 25, 2012Topics
Today's pharmaceutical industry is flooded with numerous CMOs, with Asian countries being the prime focus for big pharmaceutical companies looking to outsource. This is primarily due to the advantage of low production costs in Asia in ...
Sep. 24, 2012News & Opinions
Technology has changed many industries over the past decades. Rapidly developing computers made complex arithmetic possible and the spread of social media connected the world. The biopharma and healthcare industry is also currently ...
Aug. 13, 2012News & Opinions
Molecular Profiles, a specialist contract research and manufacturing organisation, announced that it has entered into a strategic alliance with Onyx Scientific, a contract manufacturing organisation offering chemistry services to large and ...
Jul. 18, 2012News & Opinions
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced that it has signed a biologics contract manufacturing agreement with its first Brazilian client, Recepta Biopharma in São Paulo.
Jun. 19, 2012News & Opinions
Fujifilm Diosynth Biotechnologies has announced it is further increasing its contract process development and manufacturing capabilities through the expansion of its services in mammalian cell line development/process development, and the ...
Apr. 16, 2012News & Opinions
Indian drugmaker Piramal Healthcare sees revenue potential of $1.5 billion from its new florbetaben molecule, a possible Alzheimer's treatment acquired by the company in a deal with Germany's Bayer .
The latest information directly via newsletter.